Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04742777
PHASE2

Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]

Sponsor: The University of Texas Health Science Center at San Antonio

View on ClinicalTrials.gov

Summary

The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug to prevent transplant rejection, increases the lifespan and healthspan of mice and ameliorates age-related declines in immune responsiveness, cancer survival, and cognition in laboratory animals. Investigators are conducting a translational trial to test whether rapamycin also improves life functions in humans focusing on elderly persons (aged 70-95). Substudy E will evaluate the Rapamycin and Cardiac Function.

Official title: Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Functional Consequences ((Substudy E - RAPA cMRI With LGE)

Key Details

Gender

All

Age Range

70 Years - 95 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2022-02-01

Completion Date

2026-10-16

Last Updated

2026-09-23

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

rapamycin

Taken orally 1mg daily for 8 weeks

Locations (2)

Audie L. Murphy Memorial Veterans Hospital

San Antonio, Texas, United States

The University of Texas Health Science Center at San Antonio

San Antonio, Texas, United States